Dominican Scholar
Natural Sciences and Mathematics |
Faculty Scholarship

Department of Natural Sciences and
Mathematics

7-1-2022

In Vivo Evaluation of (-)-Zampanolide Demonstrates Potent and
Persistent Antitumor Efficacy When Targeted to the Tumor Site.
Leila Takahashi-Ruiz
University of Texas Health Science Center

Joseph D Morris
Dominican University of California

Phillip Crews
University of California Santa Cruz

Tyler A Johnson
Dominican University of California

April L Risinger
University of Texas Health Science Center

https://doi.org/10.3390/molecules27134244

Survey: Let us know how this paper benefits you.
Recommended Citation
Takahashi-Ruiz, Leila; Morris, Joseph D; Crews, Phillip; Johnson, Tyler A; and Risinger, April L,
"In Vivo Evaluation of (-)-Zampanolide Demonstrates Potent and Persistent Antitumor
Efficacy When Targeted to the Tumor Site." (2022). Natural Sciences and Mathematics |
Faculty Scholarship. 89.
https://doi.org/10.3390/molecules27134244

This Article is brought to you for free and open access by the Department of Natural Sciences and
Mathematics at Dominican Scholar. It has been accepted for inclusion in Natural Sciences and
Mathematics | Faculty Scholarship by an authorized administrator of Dominican Scholar. For more
information, please contact michael.pujals@dominican.edu.

molecules
Article

In Vivo Evaluation of (−)-Zampanolide Demonstrates Potent and
Persistent Antitumor Efficacy When Targeted to the Tumor Site
Leila Takahashi-Ruiz 1 , Joseph D. Morris 2 , Phillip Crews 3 , Tyler A. Johnson 2, * and April L. Risinger 1, *
1

2

3

*

Citation: Takahashi-Ruiz, L.; Morris,
J.D.; Crews, P.; Johnson, T.A.;
Risinger, A.L. In Vivo Evaluation of
(−)-Zampanolide Demonstrates

Department of Pharmacology, Mays Cancer Center, University of Texas Health Science Center San Antonio,
San Antonio, TX 78229, USA; takahashil@livemail.uthscsa.edu
Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, USA;
joseph.morris@dominican.edu
Department of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA 95064, USA;
pcrews@ucsc.edu
Correspondence: tyler.johnson@dominican.edu (T.A.J.); risingera@uthscsa.edu (A.L.R.);
Tel.: +1-415-482-1983 (T.A.J.); +1-210-567-6267 (A.L.R.)

Abstract: Microtubule-stabilizing agents (MSAs) are a class of compounds used in the treatment
of triple-negative breast cancer (TNBC), a subtype of breast cancer where chemotherapy remains
the standard-of-care for patients. Taxanes like paclitaxel and docetaxel have demonstrated efficacy
against TNBC in the clinic, however new classes of MSAs need to be identified due to the rise
of taxane resistance in patients. (−)-Zampanolide is a covalent microtubule stabilizer that can
circumvent taxane resistance in vitro but has not been evaluated for in vivo antitumor efficacy. Here,
we determine that (−)-zampanolide has similar potency and efficacy to paclitaxel in TNBC cell
lines, but is significantly more persistent due to its covalent binding. We also provide the first
reported in vivo antitumor evaluation of (−)-zampanolide where we determine that it has potent and
persistent antitumor efficacy when delivered intratumorally. Future work on zampanolide to further
evaluate its pharmacophore and determine ways to improve its systemic therapeutic window would
make this compound a potential candidate for clinical development through its ability to circumvent
taxane-resistance mechanisms.
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1. Introduction
Breast cancer is the most common cancer diagnosed among women in the United States
and is the second leading cause of cancer death [1]. Among the different types of breast
cancer, triple negative breast cancer (TNBC) accounts for 15–20% of all breast cancers [2] and
requires an aggressive clinical course because of the high metastatic potential with elevated
rates of relapse and lower survival than other breast cancers [1]. Chemotherapy remains the
standard-of-care for patients with TNBC and some of the most effective chemotherapeutics
are microtubule-stabilizing agents (MSAs). MSAs decrease microtubule dynamicity, which
inhibits the formation of the mitotic spindle leading to antimitotic effects and disruption of other
microtubule-dependent cellular processes including protein transport, cellular signaling, and
maintenance of cell shape [3]. The taxanes are a class of MSAs that include the natural product
paclitaxel and the semi-synthetic derivative docetaxel. These taxanes are commonly used for the
treatment of TNBC, however their efficacy is hampered by drug resistance, which often occurs
through upregulation of drug efflux pumps or alterations in tubulin isotype expression [4].
The efficacy of the taxanes in TNBC demonstrates that microtubule stabilization is a validated
mechanism of treating this disease. However, there is a need to identify new classes of MSAs
that retain efficacy in clinically relevant models of taxane resistance.
(−)-Zampanolide (referred to as zampanolide in the current manuscript) is a 20membered macrolide isolated from marine sponges Fasciospongia rimosa and Cacospongia
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mycofijiensis where the absolute stereochemistry was determined by enantioselective total
synthesis to be 11S, 15S, 19S, 20S [5,6]. Zampanolide is a MSA that binds within the taxanesite on β-tubulin but is distinct from the taxanes in that it binds covalently and irreversibly
to microtubules. Zampanolide promotes microtubule stabilization and G2 /M arrest in
hematological and solid tumor models in vitro, leading to antiproliferative and cytotoxic
effects at low nanomolar concentrations [5]. The mechanism of microtubule stabilization of
zampanolide downstream of microtubule binding is shared with paclitaxel in that they both
promote the reorganization of the disordered S7-H9 M-loop into an α-helix, which leads
to helix–helix interactions and enhanced stabilization of the microtubule [7]. However,
the covalent binding between the C9 of zampanolide with H229 on β-tubulin makes this
microtubule stabilization more persistent than taxane-mediated stabilization, which allows
zampanolide to retain efficacy in taxane resistant models in vitro [5,7–10].
Covalent binding to the drug target is a validated mechanism to overcome drug resistance and this is a shared feature among other microtubule stabilizers that irreversibly bind
to tubulin, including cyclostreptin and the taccalonolides. Cyclostreptin was the first MSA
discovered to covalently bind to tubulin [11]. Although cyclostreptin maintains efficacy in Pglycoprotein [11] and βIII-tubulin [9] expressing cells due to its covalent binding, chemical
instability and low cellular potency made it a less favorable compound for further investigation. The C22,23-epoxytaccalonolides also bind covalently to β-tubulin [12] to promote
microtubule stabilization with in vitro potency similar to the taxanes, leading to antimitotic
and cytotoxic effects [13,14]. While the taccalonolides retain efficacy in taxane-resistant
models both in vitro and in vivo, they have a narrow therapeutic index with systemic
administration [9,15]. In spite of their shared covalent binding to β-tubulin [9,16] these
drugs have distinct effects on microtubule stabilization; zampanolide stabilizes the M-loop
of β-tubulin in a manner similar to paclitaxel while taccalonolide and cyclostreptin binding
is not associated with M-loop stabilization [9,13,14]. This is consistent with differences
between the effects of these drugs on the kinetics of microtubule polymerization in biochemical assays where zampanolide and paclitaxel promote an immediate stabilization in
contrast to the lag in polymerization associated with cyclostreptin or the taccalonolides [9].
These data demonstrate that zampanolide has a unique mechanism of microtubule
stabilization involving M-loop stabilization through covalent binding that is distinct from
both the taxanes and other covalent stabilizers. We hypothesize that zampanolide could be
a prime candidate for the treatment of TNBC because it has the advantage of taxane-like
M-loop stabilization, which has a known clinical benefit, through irreversible binding to
retain efficacy in taxane resistant settings. However, due to the scarcity of the zampanolide
natural product, the compound has not previously been evaluated for in vivo efficacy in any
model. Herein we describe the isolation of zampanolide and the evaluation of its potency
and efficacy in a panel of molecularly diverse TNBC cell lines in vitro, including its strong
degree of cellular persistence as compared to paclitaxel. Most importantly, we demonstrate,
for the first time, the potent anti-tumor efficacy of zampanolide in a TNBC xenograft model,
albeit with a narrow therapeutic window that required local administration.
2. Results
2.1. Tubulin Stabilization by Zampanolide
To directly compare the microtubule-stabilizing kinetics of zampanolide to other
classes of microtubule-targeted drugs, we performed a biochemical assay to monitor the
polymerization of purified tubulin heterodimers into microtubules. This assay takes advantage of the fact that microtubules are cold-labile, allowing for real-time evaluation of the
kinetics of microtubule polymerization when samples are warmed from 4 to 37 ◦ C. While
tubulin polymerizes on its own under these conditions, the rate and extent of this polymerization is enhanced by microtubule stabilizers, such as paclitaxel and zampanolide, and
suppressed by microtubule destabilizers, such as combretastatin A-4 (Figure 1). Consistent
with previous reports, zampanolide promoted the immediate polymerization of purified
tubulin with similar kinetics to those induced by paclitaxel (Figure 1). In contrast, the
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the kinetics of microtubule polymerization when samples are warmed from 4 to 37 °C.
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zampanolide was observed across TNBC lines, which is measured by comparing the final
cellular density to the density at the time of drug addition (represented by the dashed line
cellular density to the density at the time of drug addition (represented by the dashed
at y = 0 in Figure 2). While primarily antiproliferative effects were observed in the
line at y = 0 in Figure 2). While primarily antiproliferative effects were observed in the
HCC1937, BT-549, and MDA-MB-231 TNBC lines, cytotoxicity was clearly observed in
the HCC1806, HCC70, and MDA-MB-453 TNBC lines as evidenced by the curves falling
below the measure of cellular density at the time of drug addition (Figure 2). This relative
cytotoxic efficacy among TNBC lines is consistent with other microtubule stabilizing and
destabilizing agents [19], suggesting that zampanolide does not demonstrate any distinct
advantages or disadvantages in its cytotoxic efficacy against TNBC models as compared to
clinically approved drugs of this class.
The mechanistic effects of zampanolide on cellular microtubules were evaluated in HCC1937
TNBC cells by indirect immunofluorescence. As expected, zampanolide promoted an increase
in the density of interphase microtubules as evidenced by the reorganization of the microtubule
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The mechanistic effects of zampanolide on cellular microtubules were evaluated in
HCC1937 TNBC cells by indirect immunofluorescence. As expected, zampanolide promoted an increase in the density of interphase microtubules as evidenced by the reorganization of the microtubule cytoskeleton into thick microtubule bundles (Figure 3A). Additionally, cells going through mitosis also demonstrated a distinct microtubule morphology where the normal bipolar mitotic spindle is replaced with numerous microtubule asters (Figure 3B). The absence of a bipolar spindle leads to disorganization of the chromosomes, mitotic arrest, and improper segregation of chromosomes into any cells that undergo mitotic slippage. This is supported by the G2/M accumulation of MDA-MB-231
TNBC cells after treatment with zampanolide, similar to the effects of paclitaxel (Figure
3C). Together, these data demonstrate that zampanolide promotes microtubule stabilization, leading to the mitotic arrest and antiproliferative efficacy in a molecularly diverse
subset of TNBC cells in a manner similar to other MSAs.
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2.3. Zampanolide Has Persistent Efficacy In Vitro
While zampanolide and paclitaxel have similar effects on biochemical tubulin
polymerization (Figure 1) and antiproliferative potency in TNBC cells when the drug remains in the media throughout the 48 h assay period (Figure 2, Table 1), we anticipated

Molecules 2022, 27, 4244

5 of 13

2.3. Zampanolide Has Persistent Efficacy In Vitro
While zampanolide and paclitaxel have similar effects on biochemical tubulin polymerization (Figure 1) and antiproliferative potency in TNBC cells when the drug remains
in the media throughout the 48 h assay period (Figure 2, Table 1), we anticipated that the
irreversible binding of zampanolide to tubulin would provide superior in vitro efficacy
when the drug was only available for a short period prior to being washed off. This would
be relevant to the in vivo situation where the drug is actively cleared. Moreover, a strong
degree of cellular persistence following the removal of excess drug from the medium has
been associated with potent in vivo antitumor efficacy for other classes of microtubule binding drugs, including eribulin and the taccalonolides [15,20]. To evaluate cellular persistence
in vitro, we treated MDA-MB-231 cells at a low density with 10 or 50 nM zampanolide or
paclitaxel for 2 h after which the drug containing media is washed off and replaced allowing
cells to grow into colonies without any exogenous drug for an additional 10 days. Just a
2 h incubation of MDA-MB-231 cells with as little as 10 nM zampanolide was sufficient
to completely inhibit colony growth over the subsequent 10 day period (Figure 4). In
comparison, 10 nM paclitaxel had no effect on the number of colonies formed as compared
to vehicle treated cells and 50 nM had an intermediate, but non-significant effect on colony
growth (Figure 4). The cellular persistence of zampanolide is reminiscent of the activity of
the taccalonolides in this assay and demonstrates the potential advantage of zampanolide
over paclitaxel as a covalent stabilizer not only to circumvent drug resistance
Molecules 2022, 27, x FOR PEER REVIEW
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13
but also to provide long-term efficacy after acute treatment in both drug sensitive and
resistant TNBC.
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and over 100-fold more potent than docetaxel with regard to MTD [21]. However, zampanolide was determined to have no therapeutic window for antitumor efficacy with systemic administration as no decrease in tumor volume was observed at this LD50. Thus,
another tumor trial was conducted with localized intratumoral injections of zampanolide
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toxicity with up to 10% weight loss, and death in 50% of the animals 7 days post-injection. This
indicates that zampanolide is bioavailable and over 100-fold more potent than docetaxel with
regard to MTD [21]. However, zampanolide was determined to have no therapeutic window for
antitumor efficacy with systemic administration as no decrease in tumor volume was observed
at this LD50. Thus, another tumor trial was conducted with localized intratumoral injections of
zampanolide to determine whether it could promote antitumor efficacy if it was able to reach
the tumor without systemic toxicity. Animals bearing MDA-MB-231 xenografts were given
direct intratumoral injections of 15 µg zampanolide or 3 µL DMSO vehicle in 100 µL PBS on
days 0 and 7 (Figure 5A). A total dose of just 30 µg zampanolide caused a significant decrease
in tumor volume as compared to vehicle controls. A divergence in tumor growth between the
two groups was seen at day 5 with a significant difference in tumor growth by day 12 and
increasing significance at days 14 and 16 (Figure 5B,C). Zampanolide-treated tumors remained
under 1000 mm3 while vehicle treated tumors reached endpoint tumor volumes, leading to
the end of the tumor trial on day 16 (Figure 5D). Even 9 days after the final dose, zampanolide
tumors were notably smaller with a significant difference compared to vehicle-treated tumors
(Figure
5E).REVIEW
These results demonstrate that zampanolide has potent and persistent antitumor
Molecules 2022, 27,
x FOR PEER
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efficacy with low doses maintaining antitumor efficacy over an extended period in this rapidly
growing tumor model.

Figure 5. Antitumor efficacy of zampanolide in MDA-MB-231 TNBC tumors. (A) Timeline of tumor
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plot of indi-by
vidual
tumor
volumes
from comparisons.
vehicle and zampanolide
treated
animals.
(E) Final
weight
of each from
tutwo-way ANOVA
with
Sidak’s
multiple
(D) Spider
plot of
individual
tumor
volumes
mor from vehicle
and
zampanolide
treated
animals.
Significance
by and
unpaired
T-test. *
vehicle and zampanolide
treated
animals.
(E) Final
weight
of each
tumor determined
from vehicle
zampanolide
p < 0.05, *** p < 0.001, **** p < 0.0001.
treated animals. Significance determined by unpaired T-test. * p < 0.05, *** p < 0.001, **** p < 0.0001.
3. Discussion
Zampanolide is a microtubule stabilizing agent that has a unique mechanism of action from either taxanes or the taccalonolides that involves covalent binding within the
taxane site on β-tubulin and stabilization of the M-loop to promote rapid and irreversible
microtubule stabilization. We confirmed the mechanism of action of our purified zampa-
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3. Discussion
Zampanolide is a microtubule stabilizing agent that has a unique mechanism of action
from either taxanes or the taccalonolides that involves covalent binding within the taxane
site on β-tubulin and stabilization of the M-loop to promote rapid and irreversible microtubule stabilization. We confirmed the mechanism of action of our purified zampanolide
as a potent microtubule stabilizer through biochemical tubulin polymerization assays as
well as immunofluorescence imaging and cell cycle analysis. Unsurprisingly, the potency
and efficacy of zampanolide is comparable to paclitaxel in a panel of molecularly distinct
TNBC cell lines with continuous 48 h drug exposure. However, zampanolide was markedly
distinct from paclitaxel in its degree of cellular persistence such that a short, 2 h, treatment
with 10 nM zampanolide was sufficient to completely inhibit the colony forming capability
of TNBC cells over the subsequent 10-day period even after excess drug was removed
from the medium. We hypothesized that this high degree of cellular persistence would
translate to potent and persistent in vivo antitumor efficacy, which prompted the first
ever in vivo evaluation of this irreversible microtubule stabilizer. Indeed, zampanolide
is bioavailable and highly potent in vivo with an MTD of less than 1 mg/kg. However,
it has an unacceptable therapeutic window for antitumor efficacy with systemic dosing,
prompting evaluations of antitumor efficacy with intratumoral injection. As little as 30 µg
of zampanolide provided antitumor efficacy for at least a week after the final dose. This
finding demonstrates that zampanolide has potent and persistent antitumor efficacy when
targeted to the tumor site. However, further work is needed to improve the therapeutic
index of zampanolide, either by improving pharmacokinetic properties through medicinal chemistry efforts or by identifying mechanisms to improve its targeted delivery to
the tumor.
There are multiple strategies that have been employed to improve the therapeutic
window for microtubule-targeting agents (MTAs) in vivo. The most striking example has
been the repurposing of highly toxic MTAs including the maytansine-derivative DM1 and
the dolastatin-derivative MMAE as warheads for antibody-drug conjugates [22]. Additionally, the therapeutic index of paclitaxel can be further improved through the linkage
of a 1,18-octadecanedioic acid, which forms a noncovalent complex with human serum
albumin [23]. To take advantage of either of these approaches to improve the therapeutic
index of zampanolide, it is critical to first understand its functional pharmacophore and
potential chemical liabilities. While the chemically fragile side chain of zampanolide may
be a liability, absence of this moiety in the metabolic precursor dactylolide and synthetic
mimetics results in compounds with a significant reduction in cellular potency [10,24,25].
In contrast, single digit nanomolar potency can be retained upon replacement of the THP
ring of zampanolide with a morpholine, which can serve as a convenient site for modifications to improve physiochemical properties and enhance tumor targeting while retaining
binding within the taxane site [26]. Structure-activity relationship studies from zampanolide analogs isolated alongside the natural product demonstrate an unanticipated degree
of flexibility in the macrolide core for retaining the potency and mechanism of action of
zampanolide [27]. Over 45 analogs of this chemotype have been reported to date (mostly
synthetic) [10,18,24–28] demonstrating that there is potential to modify zampanolide to
improve its physiochemical and tumor-targeting properties.
Herein, we demonstrate that the exquisite in vivo potency of zampanolide offers the
opportunity to explore the antitumor efficacy of zampanolide analogs with improved
pharmacokinetic and tumor targeting properties even with small quantities of starting
material. However, any derivatives that demonstrate an improved therapeutic window
would still require a substantial increase in scale for true clinical development. The structure
of this chemotype with only four chiral centers makes zampanolide amenable to total
synthesis with results reported from multiple different research groups. To date, there have
been over a dozen total synthesis of zampanolide and or variations of its macrolactone
core ranging from 28 to 13 steps [29–34]. While these synthetic strategies are not trivial, the
identification of a highly potent zampanolide derivative with an acceptable therapeutic
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window in vivo could provide the impetus to make the considerable synthetic efforts that
led to the clinical success of the sponge-derived halichondrin derivative eribulin, which
possesses 19 chiral centers and required 62 steps at the time of FDA approval [35]. In
summary, zampanolide has a unique mechanism of action from any clinically approved
MSA that allows it to circumvent drug resistance in vitro and provide potent and persistent
in vivo antitumor efficacy, albeit with a narrow therapeutic window that will require
further optimization through medicinal chemistry efforts to develop this chemotype for
the treatment taxane-resistant disease.
4. Materials and Methods
4.1. General Experimental
HPLC purification of (−)-zampanolide was performed on a Luna 5 µm, C18(2) 100 Å
10 × 250 mm column (Phenomenex, Inc., Torrance, CA, USA) in conjunction with a
4.0 × 3.0 mm C18 (Octadecyl) guard column and cartridge (holder part number: KJ04282, cartridge part number: AJ0-4287, Phenomenex, Inc.). Compound detection was
measured by means of a single wavelength (λ max = 230 nM) using an Applied Biosystems (Waltham, MA, USA) 759a UV detector. NMR experiments were performed on a
Varian spectrometer (equipped with a 5 mm triple-resonance probe) at 400 MHz for 1 H and
100 MHz for 13 C experiments.
4.2. Isolation of (−)-Zampanolide
Samples of C. mycofijiensis were processed according to previous reports [36]. During
the process of scale up isolation for fijianolide B (laulimalide), a repository fat-soluble
dichloromethane-methanol extract (coded DMM), not previously processed due to its high
lipophilic content, was further partitioned using 100 mL H2 O (coded DMMW) and 100
mL dichloromethane (coded DMMF). The DMMF was evaporated and further partitioned
with 100 mL 90:10 MeOH:H2 O (coded DMMFM) and 100 mL hexanes (coded DMMFH)
yielding a total of 315 mg DMMFM and 1169 mg DMMFH. Semi-preparative HPLC of
the DMMFM extract (315 mg) using a reversed-phased gradient (30:70 CH3 CN:H2 O up
to 80:20 at 50 min) yielded approximately 1.8% (−)-zampanolide from this extract, which
was dried under a nitrogen stream, purged under argon, and stored in an amber vial
in a dark desiccator under vacuum. NMR of purified (−)-zampanolide is available in
the Supplementary Materials. This compound is referred to as zampanolide throughout
the article.
4.3. Cell Lines
Human TNBC cell lines MDA-MB-231, MDA-MB-453, HCC1806, HCC70, and HCC1937
were received from ATCC (Manassas, VA, USA). BT-549 cells were obtained from the
Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC. BT549, HCC1806, HCC70, and HCC1937 were cultured in RPMI 1640 medium (Corning,
Corning, NY, USA) supplemented with up to 10% FBS (Corning) and 50 µg/mL gentamicin
(ThermoFisher Scientific, Waltham, MA, USA). MDA-MB-231 and MDA-MB-453 were
cultured in modified IMEM (1X) supplemented with L-glutamine and up to 10% FBS
and 50 µg/mL gentamicin. Cell line identity was authenticated by STR-based profiling
(Genetica DNA Laboratories, Cincinnati, OH, USA). All cells were grown at 37 ◦ C and 5%
CO2 in an incubator and routinely tested for mycoplasma contamination.
4.4. Sulforhodamine B Assay
Cells were seeded into a 96-well plate (Corning) at an optimal density to maintain final
readouts in the linear range of the assay. After adhering overnight, the cells were treated
zampanolide at the indicated concentrations in 0.5% DMSO (Fisher Scientific, Waltham,
MA, USA) for 48 h. A separate time zero plate was fixed with 10% trichloroacetic acid
(Sigma-Aldrich, St. Louis, MO, USA) to provide a readout of cellular density at the time
of drug addition. After treatment, the cells were fixed with 10% trichloroacetic acid for a
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minimum of 1 h. The cells were then stained with sulforhodamine B dye (Sigma-Aldrich)
for 30 min. Excess dye was washed off and the cellular-bound dye was solubilized in 200 µL
of 10 mM Tris before reading the optical density at 560 nm on the Spectramax plate reader
running SoftMax Pro 5.4 (Molecular Devices, San Jose, CA, USA). The percent growth or
cytotoxicity of cells during the treatment period was determined as compared to the time
zero plate (y = 0) and vehicle treated wells (y = 100) and replicates graphed with error bars
representing SEM. Concentrations that caused a 50% inhibition of cell growth (GI50 ) and
total growth inhibition (TGI) were determined by non-linear regression analysis of the data
using Prism (Graphpad, San Diego, CA, USA). Data are from 3 independent experiments
each run in triplicate ± SEM.
4.5. Tubulin Polymerization Assay
The polymerization of purified porcine tubulin (Cytoskeleton, Denver, CO) was performed in GPEM buffer (80 mM PIPES pH 6.9, 2 mM MgCl2 , 0.5 mM EGTA, and 1 mM
GTP) in 10% glycerol. All components were kept on ice during preparation. Zampanolide,
paclitaxel (Sigma-Aldrich), taccalonolide AF [13], or combretastatin A-4 (Sigma-Aldrich)
were brought up as 2 mM stocks in DMSO. 1 µL of each of the 2 mM compound stocks were
added to their respective individual wells of a 96-well plate in GPEM buffer to give a final
concentration of 20 µM in 100 µL. 20 µM tubulin in GPEM was added immediately to each
well before inserting the plate to be read by a pre-warmed 37 °C SpectraMax microplate
reader (Molecular Devices, San Jose, CA, USA). Microtubule polymerization was monitored
by measuring the change in absorbance at 340 nm every minute for an hour. Data were
recorded and analyzed using SoftMax Pro 5.4 (Molecular Devices, San Jose, CA, USA). Data
are from two independent experiments with error bars showing SEM at each time point.
4.6. Cell Cycle Analysis
MDA-MB-231 cells were seeded in 6 well plates at a density of 1 × 106 cells/mL. After
adhering overnight, the cells were treated with 10 nM or 50 nM paclitaxel, zampanolide
or DMSO vehicle control for 20 h at indicated concentrations. Cells were harvested by
scraping, washed with PBS, centrifuged at 450 g for 5 min and resuspended in 300 µL
Krishan’s reagent (0.05 mg/mL propidium iodide, 1 mg/mL sodium citrate, 0.02 mg/mL
ribonuclease A, 0.3% IGEPAL). Cell cycle distribution was analyzed based on cellular
propidium iodide incorporation by flow cytometry using a FACS Calibur (BD Biosciences,
Franklin Lakes, NJ, USA) and FlowJo software (FlowJo, Ashland, OR, USA).
4.7. Persistence Assay
MDA-MB-231 cells were diluted to a concentration of 100 cells/mL to seed 200 cells
per plate with 2 mL of media in 60 cm dishes. After adhering overnight, cells were treated
with 10 nM or 50 nM zampanolide or paclitaxel for two hours. The plates were gently
rinsed with PBS before replacing with 2 mL of fresh IMEM+ 5% FBS media. The cells were
left to grow into colonies for 10 days before fixing with 0.5% crystal violet in 20% methanol
and visible colonies counted from two independent replicates. Significance between was
determined using a one-way ANOVA with Sidak’s posthoc test for multiple comparisons.
4.8. Indirect Immunofluorescence
HCC1937 cells were seeded on coverslips in 24-well plates (Corning) and left to adhere
overnight. Cells were treated with either 100 nM zampanolide or DMSO vehicle control
for 18 h and then fixed with 100% methanol for 5 min. Indirect immunofluorescence was
used to detect β-tubulin using a primary (Sigma-Aldrich, T-4026, 1:400) and a secondary
conjugated to FITC (Sigma-Aldrich, F-3008, 1:200) and stained with 0.1 µg/mL DAPI
(Sigma-Aldrich). Images were acquired on an i80 fluorescence microscope (Nikon, Tokyo,
Japan) by compressing multiple y-stacked images using NIS elements software (Nikon).
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4.9. Animals & Tumor Trial
Six-week-old female athymic nude mice were purchased from Envigo (Indianapolis,
IN, USA). Tumors were established by injecting MDA-MB-231 tumor fragments bilaterally
into the flank until the mean tumor volume reached 200 mm3 and all tumors included in
the trial were greater than 50 mm3 . For systemic dosing, a dose of 1.0 mg/kg zampanolide
was given by i.p. injection in vehicle (n = 7 mice, 13 tumors) and compared to vehicle
treated controls (n = 5 mice, 10 tumors). For local intratumoral injections, mice were given
two doses of 15 µg zampanolide in vehicle (n = 5 mice, 10 tumors) on days 0 and 7 and
compared to animals treated intratumorally with vehicle alone (n = 6 mice, 11 tumors).
Tumor volume was measured by calipers (length × width × height) three times a week
and weight monitored throughout the trials until day 16 when the first tumor reached
the endpoint volume of 2000 mm3 in accordance with our IACUC protocol. Statistical
differences between the vehicle and zampanolide treated groups were determined by a
two- way ANOVA (drug * time) with Sidak’s posthoc test for multiple comparisons. All
tumors were collected and weighed at this endpoint and significance between the vehicle
and zampanolide treated groups determined by an unpaired t-test.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/molecules27134244/s1, Figure S1. 1 H NMR spectrum of (−)-zampanolide in benzene-d6 at
400 MHz, Figure S2. 13 C NMR spectrum of (−)-zampanolide in benzene-d6 at 100 MHz.
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